Lawrence Corey1, Peter B Gilbert1, Michal Juraska1, David C Montefiori1, Lynn Morris1, Shelly T Karuna1, Srilatha Edupuganti1, Nyaradzo M Mgodi1, Allan C deCamp1, Erika Rudnicki1, Yunda Huang1, Pedro Gonzales1, Robinson Cabello1, Catherine Orrell1, Javier R Lama1, Fatima Laher1, Erica M Lazarus1, Jorge Sanchez1, Ian Frank1, Juan Hinojosa1, Magdalena E Sobieszczyk1, Kyle E Marshall1, Pamela G Mukwekwerere1, Joseph Makhema1, Lindsey R Baden1, James I Mullins1, Carolyn Williamson1, John Hural1, M Juliana McElrath1, Carter Bentley1, Simbarashe Takuva1, Margarita M Gomez Lorenzo1, David N Burns1, Nicole Espy1, April K Randhawa1, Nidhi Kochar1, Estelle Piwowar-Manning1, Deborah J Donnell1, Nirupama Sista1, Philip Andrew1, James G Kublin1, Glenda Gray1, Julie E Ledgerwood1, John R Mascola1, Myron S Cohen1. 1. From the Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center (L.C., P.B.G., M.J., S.T.K., A.C.C., E.R., Y.H., K.E.M., J. Hural, M.J.M.E., C.B., S.T., N.E., A.K.R., N.K., D.J.D., J.G.K., G.G.), and the Departments of Global Health, Microbiology, and Medicine, University of Washington (J.I.M.), Seattle; the Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center (D.C.M.), and FHI 360 (N.S., P.A.), Durham, and the Institute for Global Health and Infectious Disease, University of North Carolina, Chapel Hill (M.S.C.) - both in North Carolina; the National Institute for Communicable Diseases of the National Health Laboratory Service (L.M.) and the Antibody Immunity Research Unit, Faculty of Health Sciences (L.M.), and the Perinatal HIV Research Unit, Faculty of Health Sciences (F.L., E.M.L., S.T.), University of the Witwatersrand, Johannesburg, the Desmond Tutu HIV Centre, Department of Medicine and Institute of Infectious Disease and Molecular Medicine (C.O.), and the Division of Medical Virology (C.W.), University of Cape Town, Cape Town, the School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria (S.T.), and the South African Medical Research Council, Tygerberg (G.G.) - all in South Africa; the Department of Medicine, Division of Infectious Diseases, Emory University, Atlanta (S.E.); the University of Zimbabwe College of Health Sciences Clinical Trials Research Centre, Harare, Zimbabwe (N.M.M., P.G.M.); Servicio de Enfermedades Infecciosas y Tropicales, Hospital Nacional Dos de Mayo (P.G.), Asociación Civil Via Libre (R.C.), Asociación Civil Impacta Salud y Educación (J.R.L.), and Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, Universidad Nacional Mayor de San Marcos (J.S.), Lima, and Association Civil Selva Amazónica, Clinical Research Site, Iquitos (J. Hinojosa) - both in Peru; the Infectious Diseases Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.); the Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York (M.E.S.); Botswana Harvard AIDS Institute, Gaborone, Botswana (J.M.); Brigham and Women's Hospital, Harvard Medical School, Boston (L.R.B.); and the Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Rockville (M.M.G.L.), the Prevention Sciences Program, Division of AIDS (D.N.B.), and the Vaccine Research Center (J.E.L., J.R.M.), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, and Johns Hopkins University School of Medicine, Baltimore (E.P.-M.) - all in Maryland.
Abstract
BACKGROUND: Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODS: We enrolled at-risk cisgender men and transgender persons in the Americas and Europe in the HVTN 704/HPTN 085 trial and at-risk women in sub-Saharan Africa in the HVTN 703/HPTN 081 trial. Participants were randomly assigned to receive, every 8 weeks, infusions of a bnAb (VRC01) at a dose of either 10 or 30 mg per kilogram (low-dose group and high-dose group, respectively) or placebo, for 10 infusions in total. HIV-1 testing was performed every 4 weeks. The VRC01 80% inhibitory concentration (IC80) of acquired isolates was measured with the TZM-bl assay. RESULTS: Adverse events were similar in number and severity among the treatment groups within each trial. Among the 2699 participants in HVTN 704/HPTN 085, HIV-1 infection occurred in 32 in the low-dose group, 28 in the high-dose group, and 38 in the placebo group. Among the 1924 participants in HVTN 703/HPTN 081, infection occurred in 28 in the low-dose group, 19 in the high-dose group, and 29 in the placebo group. The incidence of HIV-1 infection per 100 person-years in HVTN 704/HPTN 085 was 2.35 in the pooled VRC01 groups and 2.98 in the placebo group (estimated prevention efficacy, 26.6%; 95% confidence interval [CI], -11.7 to 51.8; P = 0.15), and the incidence per 100 person-years in HVTN 703/HPTN 081 was 2.49 in the pooled VRC01 groups and 3.10 in the placebo group (estimated prevention efficacy, 8.8%; 95% CI, -45.1 to 42.6; P = 0.70). In prespecified analyses pooling data across the trials, the incidence of infection with VRC01-sensitive isolates (IC80 <1 μg per milliliter) per 100 person-years was 0.20 among VRC01 recipients and 0.86 among placebo recipients (estimated prevention efficacy, 75.4%; 95% CI, 45.5 to 88.9). The prevention efficacy against sensitive isolates was similar for each VRC01 dose and trial; VRC01 did not prevent acquisition of other HIV-1 isolates. CONCLUSIONS: VRC01 did not prevent overall HIV-1 acquisition more effectively than placebo, but analyses of VRC01-sensitive HIV-1 isolates provided proof-of-concept that bnAb prophylaxis can be effective. (Supported by the National Institute of Allergy and Infectious Diseases; HVTN 704/HPTN 085 and HVTN 703/HPTN 081 ClinicalTrials.gov numbers, NCT02716675 and NCT02568215.).
BACKGROUND: Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODS: We enrolled at-risk cisgender men and transgender persons in the Americas and Europe in the HVTN 704/HPTN 085 trial and at-risk women in sub-Saharan Africa in the HVTN 703/HPTN 081 trial. Participants were randomly assigned to receive, every 8 weeks, infusions of a bnAb (VRC01) at a dose of either 10 or 30 mg per kilogram (low-dose group and high-dose group, respectively) or placebo, for 10 infusions in total. HIV-1 testing was performed every 4 weeks. The VRC01 80% inhibitory concentration (IC80) of acquired isolates was measured with the TZM-bl assay. RESULTS: Adverse events were similar in number and severity among the treatment groups within each trial. Among the 2699 participants in HVTN 704/HPTN 085, HIV-1 infection occurred in 32 in the low-dose group, 28 in the high-dose group, and 38 in the placebo group. Among the 1924 participants in HVTN 703/HPTN 081, infection occurred in 28 in the low-dose group, 19 in the high-dose group, and 29 in the placebo group. The incidence of HIV-1 infection per 100 person-years in HVTN 704/HPTN 085 was 2.35 in the pooled VRC01 groups and 2.98 in the placebo group (estimated prevention efficacy, 26.6%; 95% confidence interval [CI], -11.7 to 51.8; P = 0.15), and the incidence per 100 person-years in HVTN 703/HPTN 081 was 2.49 in the pooled VRC01 groups and 3.10 in the placebo group (estimated prevention efficacy, 8.8%; 95% CI, -45.1 to 42.6; P = 0.70). In prespecified analyses pooling data across the trials, the incidence of infection with VRC01-sensitive isolates (IC80 <1 μg per milliliter) per 100 person-years was 0.20 among VRC01 recipients and 0.86 among placebo recipients (estimated prevention efficacy, 75.4%; 95% CI, 45.5 to 88.9). The prevention efficacy against sensitive isolates was similar for each VRC01 dose and trial; VRC01 did not prevent acquisition of other HIV-1 isolates. CONCLUSIONS: VRC01 did not prevent overall HIV-1 acquisition more effectively than placebo, but analyses of VRC01-sensitive HIV-1 isolates provided proof-of-concept that bnAb prophylaxis can be effective. (Supported by the National Institute of Allergy and Infectious Diseases; HVTN 704/HPTN 085 and HVTN 703/HPTN 081 ClinicalTrials.gov numbers, NCT02716675 and NCT02568215.).
Authors: Marcella Sarzotti-Kelsoe; Robert T Bailer; Ellen Turk; Chen-li Lin; Miroslawa Bilska; Kelli M Greene; Hongmei Gao; Christopher A Todd; Daniel A Ozaki; Michael S Seaman; John R Mascola; David C Montefiori Journal: J Immunol Methods Date: 2013-12-01 Impact factor: 2.303
Authors: Amarendra Pegu; Zhi-yong Yang; Jeffrey C Boyington; Lan Wu; Sung-Youl Ko; Stephen D Schmidt; Krisha McKee; Wing-Pui Kong; Wei Shi; Xuejun Chen; John-Paul Todd; Norman L Letvin; Jinghe Huang; Martha C Nason; James A Hoxie; Peter D Kwong; Mark Connors; Srinivas S Rao; John R Mascola; Gary J Nabel Journal: Sci Transl Med Date: 2014-07-02 Impact factor: 17.956
Authors: J E Ledgerwood; E E Coates; G Yamshchikov; J G Saunders; L Holman; M E Enama; A DeZure; R M Lynch; I Gordon; S Plummer; C S Hendel; A Pegu; M Conan-Cibotti; S Sitar; R T Bailer; S Narpala; A McDermott; M Louder; S O'Dell; S Mohan; J P Pandey; R M Schwartz; Z Hu; R A Koup; E Capparelli; J R Mascola; B S Graham Journal: Clin Exp Immunol Date: 2015-09-24 Impact factor: 4.330
Authors: Rebecca M Lynch; Eli Boritz; Emily E Coates; Adam DeZure; Patrick Madden; Pamela Costner; Mary E Enama; Sarah Plummer; Lasonji Holman; Cynthia S Hendel; Ingelise Gordon; Joseph Casazza; Michelle Conan-Cibotti; Stephen A Migueles; Randall Tressler; Robert T Bailer; Adrian McDermott; Sandeep Narpala; Sijy O'Dell; Gideon Wolf; Jeffrey D Lifson; Brandie A Freemire; Robert J Gorelick; Janardan P Pandey; Sarumathi Mohan; Nicolas Chomont; Remi Fromentin; Tae-Wook Chun; Anthony S Fauci; Richard M Schwartz; Richard A Koup; Daniel C Douek; Zonghui Hu; Edmund Capparelli; Barney S Graham; John R Mascola; Julie E Ledgerwood Journal: Sci Transl Med Date: 2015-12-23 Impact factor: 17.956
Authors: Ron Diskin; Johannes F Scheid; Paola M Marcovecchio; Anthony P West; Florian Klein; Han Gao; Priyanthi N P Gnanapragasam; Alexander Abadir; Michael S Seaman; Michel C Nussenzweig; Pamela J Bjorkman Journal: Science Date: 2011-10-27 Impact factor: 47.728
Authors: Kenneth H Mayer; Kelly E Seaton; Yunda Huang; Nicole Grunenberg; Abby Isaacs; Mary Allen; Julie E Ledgerwood; Ian Frank; Magdalena E Sobieszczyk; Lindsey R Baden; Benigno Rodriguez; Hong Van Tieu; Georgia D Tomaras; Aaron Deal; Derrick Goodman; Robert T Bailer; Guido Ferrari; Ryan Jensen; John Hural; Barney S Graham; John R Mascola; Lawrence Corey; David C Montefiori Journal: PLoS Med Date: 2017-11-14 Impact factor: 11.069
Authors: Peter B Gilbert; Michal Juraska; Allan C deCamp; Shelly Karuna; Srilatha Edupuganti; Nyaradzo Mgodi; Deborah J Donnell; Carter Bentley; Nirupama Sista; Philip Andrew; Abby Isaacs; Yunda Huang; Lily Zhang; Edmund Capparelli; Nidhi Kochar; Jing Wang; Susan H Eshleman; Kenneth H Mayer; Craig A Magaret; John Hural; James G Kublin; Glenda Gray; David C Montefiori; Margarita M Gomez; David N Burns; Julie McElrath; Julie Ledgerwood; Barney S Graham; John R Mascola; Myron Cohen; Lawrence Corey Journal: Stat Commun Infect Dis Date: 2017-06-06
Authors: Amarendra Pegu; Ling Xu; Megan E DeMouth; Giulia Fabozzi; Kylie March; Cassandra G Almasri; Michelle D Cully; Keyun Wang; Eun Sung Yang; Joana Dias; Christine M Fennessey; Jason Hataye; Ronnie R Wei; Ercole Rao; Joseph P Casazza; Wanwisa Promsote; Mangaiarkarasi Asokan; Krisha McKee; Stephen D Schmidt; Xuejun Chen; Cuiping Liu; Wei Shi; Hui Geng; Kathryn E Foulds; Shing-Fen Kao; Amy Noe; Hui Li; George M Shaw; Tongqing Zhou; Constantinos Petrovas; John-Paul Todd; Brandon F Keele; Jeffrey D Lifson; Nicole A Doria-Rose; Richard A Koup; Zhi-Yong Yang; Gary J Nabel; John R Mascola Journal: Cell Rep Date: 2022-01-04 Impact factor: 9.423
Authors: Jacqueline M Brady; Meredith Phelps; Scott W MacDonald; Evan C Lam; Adam Nitido; Dylan Parsons; Christine L Boutros; Cailin E Deal; Wilfredo F Garcia-Beltran; Serah Tanno; Harini Natarajan; Margaret E Ackerman; Vladimir D Vrbanac; Alejandro B Balazs Journal: Sci Transl Med Date: 2022-07-27 Impact factor: 19.319
Authors: Hui Li; Shuyi Wang; Fang-Hua Lee; Ryan S Roark; Alex I Murphy; Jessica Smith; Chengyan Zhao; Juliette Rando; Neha Chohan; Yu Ding; Eunlim Kim; Emily Lindemuth; Katharine J Bar; Ivona Pandrea; Cristian Apetrei; Brandon F Keele; Jeffrey D Lifson; Mark G Lewis; Thomas N Denny; Barton F Haynes; Beatrice H Hahn; George M Shaw Journal: J Virol Date: 2021-03-03 Impact factor: 5.103
Authors: Yiming Yin; Brian D Quinlan; Tianling Ou; Yan Guo; Wenhui He; Michael Farzan Journal: Proc Natl Acad Sci U S A Date: 2021-07-20 Impact factor: 11.205
Authors: Justin Pollara; Matthew Zirui Tay; R Whitney Edwards; Derrick Goodman; Andrew R Crowley; Robert J Edwards; David Easterhoff; Haleigh E Conley; Taylor Hoxie; Thaddeus Gurley; Caroline Jones; Emily Machiele; Marina Tuyishime; Elizabeth Donahue; Shalini Jha; Rachel L Spreng; Thomas J Hope; Kevin Wiehe; Max M He; M Anthony Moody; Kevin O Saunders; Margaret E Ackerman; Guido Ferrari; Georgia D Tomaras Journal: Front Immunol Date: 2021-05-20 Impact factor: 7.561
Authors: Daniel B Reeves; Morgane Rolland; Bethany L Dearlove; Yifan Li; Merlin L Robb; Joshua T Schiffer; Peter Gilbert; E Fabian Cardozo-Ojeda; Bryan T Mayer Journal: J R Soc Interface Date: 2021-06-30 Impact factor: 4.293